For biotech Abliva, the main focus for 2023 has been the FALCON study, a potentially registrational, global, phase II study with lead candidate KL1333. In June, Abliva began dosing patients, and yesterday the company announced that the goal of enrolling 40 patients for Wave 1 has been met. BioStock spoke to Dag Nesse, Vice President of Clinical Operations, to learn more.

Read the article at biostock.se:

https://www.biostock.se/en/2023/12/abliva-reaches-enrollment-goal/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

https://news.cision.com/abliva/r/biostock-abliva-reaches-enrollment-goal,c3897621

(c) 2023 Cision. All rights reserved., source Press Releases - English